Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral Therapy

接受抗逆转录病毒治疗可减少艾滋病毒感染妇女的不良分娩结果

基本信息

项目摘要

Background Implementation of 3-drug antiretroviral therapy (ART) for prevention of mother to child transmission of HIV (PMTCT) has dramatically decreased vertical transmission of HIV globally. However, recent evidence suggests that women on ART have exceptionally high risk of stillbirth, preterm delivery and small for gestational age infants. Though reasons for adverse birth outcomes are unknown, a growing number of studies have found that hypertension is an important risk factor, leading us to hypothesize that maternal endothelial dysfunction causes adverse birth outcomes among HIV-infected women on ART. Candidate I first contributed to the field of PMTCT 16 years ago when I lived in South Africa and ran the first local NGO to provide antiretroviral prophylaxis in pregnancy. I decided to pursue a research career in PMTCT and adverse birth outcomes during my Infectious Diseases fellowship, after performing a large birth surveillance study in Botswana that found strikingly high rates of adverse birth outcomes and hypertension among women with well-controlled HIV. I am applying for a 5-year K23 Career Development Award that builds on findings from my fellowship study. A K23 award will provide the necessary training and experience needed to become an independent investigator studying drug safety in pregnancy, identifying mechanisms underlying adverse birth outcomes and testing interventions to improve pregnancy outcomes among HIV-infected women. Mentoring My primary mentor, Dr. Roger Shapiro, has conducted clinical trials, research on childhood mortality, and birth outcomes research in Botswana for more than 15 years and has been my research mentor since residency. Together we have identified an excellent mentoring team including Dr. Paige Williams (a biostatistician with expertise in studies of drug safety in pregnancy) and Dr. Raina Fichorova (an OB/GYN with 20 years experience running a lab in obstetric immunology). Research Using data collected in an ongoing large birth surveillance study in Botswana, and creating a nested cohort within this surveillance study, my study will 1) establish the role of hypertension in adverse pregnancy outcomes and 2) evaluate the role of low progesterone and chronic inflammation as mechanisms of adverse birth outcomes. I will evaluate whether HIV-status, specific ART regimens and/or the timing of ART initiation influence hypertension, progesterone level and markers of chronic inflammation. These combined analyses are critical first steps in the design of a larger longitudinal cohort to further elucidate mechanisms of adverse birth outcomes among HIV-infected women on ART. This will lead to interventions to improve birth outcomes among HIV-infected women. Training The research objectives are supported by a training plan that includes obtaining an MSc in Epidemiology, further training in the pathophysiology of adverse birth outcomes and a grant support and development program through Harvard Catalyst.
背景实施3种药物抗逆转录病毒治疗(ART)预防母婴感染

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis.
  • DOI:
    10.1016/j.eclinm.2020.100573
  • 发表时间:
    2020-11
  • 期刊:
  • 影响因子:
    15.1
  • 作者:
    Kanters S;Vitoria M;Zoratti M;Doherty M;Penazzato M;Rangaraj A;Ford N;Thorlund K;Anis PAH;Karim ME;Mofenson L;Zash R;Calmy A;Kredo T;Bansback N
  • 通讯作者:
    Bansback N
What will it take to refute the possible safety signal for dolutegravir and neural tube defects?
如何反驳多替拉韦和神经管缺陷可能存在的安全信号?
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rebecca Marie Zash其他文献

Rebecca Marie Zash的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rebecca Marie Zash', 18)}}的其他基金

Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
将艾滋病毒预防与产后护理联系起来:卡博特韦-LA PrEP 在博茨瓦纳高危母乳喂养人群中的安全性、有效性和可行性
  • 批准号:
    10494175
  • 财政年份:
    2021
  • 资助金额:
    $ 16.44万
  • 项目类别:
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
将艾滋病毒预防与产后护理联系起来:卡博特韦-LA PrEP 在博茨瓦纳高危母乳喂养人群中的安全性、有效性和可行性
  • 批准号:
    10676833
  • 财政年份:
    2021
  • 资助金额:
    $ 16.44万
  • 项目类别:
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
将艾滋病毒预防与产后护理联系起来:卡博特韦-LA PrEP 在博茨瓦纳高危母乳喂养人群中的安全性、有效性和可行性
  • 批准号:
    10403232
  • 财政年份:
    2021
  • 资助金额:
    $ 16.44万
  • 项目类别:
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral Therapy
接受抗逆转录病毒治疗可减少艾滋病毒感染妇女的不良分娩结果
  • 批准号:
    9349091
  • 财政年份:
    2017
  • 资助金额:
    $ 16.44万
  • 项目类别:

相似海外基金

The role of antihypertensive agents in renal and vascular complications in a model of hypertension and diabetes
抗高血压药物在高血压和糖尿病模型中肾脏和血管并发症中的作用
  • 批准号:
    nhmrc : 145854
  • 财政年份:
    2001
  • 资助金额:
    $ 16.44万
  • 项目类别:
    NHMRC Postgraduate Scholarships
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    6125791
  • 财政年份:
    1997
  • 资助金额:
    $ 16.44万
  • 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    2487342
  • 财政年份:
    1997
  • 资助金额:
    $ 16.44万
  • 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    2839029
  • 财政年份:
    1997
  • 资助金额:
    $ 16.44万
  • 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    6330091
  • 财政年份:
    1997
  • 资助金额:
    $ 16.44万
  • 项目类别:
ANTIHYPERTENSIVE AGENTS FROM RANUNCULACEAE
毛茛科抗高血压药
  • 批准号:
    2217036
  • 财政年份:
    1993
  • 资助金额:
    $ 16.44万
  • 项目类别:
ANTIHYPERTENSIVE AGENTS FROM RANUNCULACEAE
毛茛科抗高血压药
  • 批准号:
    3343932
  • 财政年份:
    1993
  • 资助金额:
    $ 16.44万
  • 项目类别:
ANTIHYPERTENSIVE AGENTS FROM RANUNCULACEAE
毛茛科抗高血压药
  • 批准号:
    2217037
  • 财政年份:
    1993
  • 资助金额:
    $ 16.44万
  • 项目类别:
CANNABINOIDS AS ANTIHYPERTENSIVE AGENTS
大麻素作为抗高血压药
  • 批准号:
    3500707
  • 财政年份:
    1985
  • 资助金额:
    $ 16.44万
  • 项目类别:
Antihypertensive Agents of Kudzu: Possible Chemical Utilization of a Southeastern Pest Vine
葛根的抗高血压剂:东南部害虫藤蔓的可能化学利用
  • 批准号:
    7905238
  • 财政年份:
    1979
  • 资助金额:
    $ 16.44万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了